An attenuated vaccine is a vaccine created by reducing the virulence of a pathogen, but still keeping it viable (or "live"). Attenuation takes an infectious agent and alters it so that it becomes harmless or less virulent. These vaccines contrast to those produced by "killing" the virus (inactivated vaccine).
Examples of live attenuated) vaccines include: Viral: measles vaccine, mumps vaccine, rubella vaccine and live attenuated influenza vaccine (the seasonal flu nasal spray and the 2009 H1N1 flu nasal spray), etc; Bacterial: BCG vaccine, oral typhoid vaccine and epidemic typhus vaccine.

The global Live Attenuated Vaccines market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Live Attenuated Vaccines volume and value at global level, regional level and company level. From a global perspective, this report represents overall Live Attenuated Vaccines market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Live Attenuated Vaccines in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Live Attenuated Vaccines manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
GlaxoSmithKline
Merck
Pfizer
Astellas Pharma
Johnson & Johnson
CSL
Sanofi
Serum Institute Of India

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Bacterial
Viral

Segment by Application
Hospitals
Clinics
Research Institutes
Others